Wilson Sonsini, Davis Polk, Fangda, Jingtian on $470 mln WuXi XDC Hong Kong IPO
PRC law firm Fangda Partners and U.S. law firm Wilson Sonsini Goodrich & Rosati have advised Chinese medical research group WuXi XDC on its $470 million Hong Kong IPO, the third-largest new share sale in the city in 2023. Davis Polk & Wardwell and Jingtian & Gongcheng acted for the underwriters.
Nishimura, AMT, Fangda advise on $274 mln Japan optics deal
Japanese law firm Nishimura & Asahi and PRC firm Fangda Partners have represented U.S. vision systems company Cognex on its $273.5 million deal to buy optical component producer Moritex Corporation from Chinese private equity firm Trustar Capital, which was advised by Anderson Mori & Tomotsune.
STB, Freshies lead on Cainiao’s planned $1 bln IPO
Simpson Thacher & Bartlett and Fangda Partners are advising the Alibaba Group and its logistics arm, Cainiao Smart Logistics Network, on Cainiao’s proposed IPO on the Hong Kong Exchange, with Freshfields Bruckhaus Deringer and Jingtian & Gongcheng acting for the sponsors.
Shearman, Davis Polk lead on Chinese cell therapy developer’s $300 mln HK IPO
Shearman & Sterling, Fangda Partners and Tian Yuan Law Firm have advised Chinese cancer cell therapy developer JW Therapeutics on its $300 million IPO in Hong Kong, with Davis Polk & Wardwell and Commerce & Finance Law Offices counselling the joint sponsors and underwriters.